Saridegib

Saridegib

Saridegib is a small molecule inhibitor that targets the Hedgehog signaling pathway. It was developed by Infinity Pharmaceuticals and was in clinical trials for the treatment of various types of cancer, including basal cell carcinoma and pancreatic cancer. However, the development of Saridegib was discontinued in 2012 due to adverse side effects.

Mechanism of Action

Saridegib works by inhibiting the Hedgehog signaling pathway, a pathway that is critical for cell growth and differentiation. In particular, it targets the Smoothened protein, a key component of the Hedgehog pathway. By inhibiting Smoothened, Saridegib prevents the activation of the Hedgehog pathway, thereby inhibiting the growth of cancer cells.

Clinical Trials

Saridegib was tested in several clinical trials for its efficacy in treating various types of cancer. In a Phase II trial for pancreatic cancer, however, the drug was found to have severe side effects and did not improve survival rates. As a result, Infinity Pharmaceuticals decided to discontinue the development of Saridegib in 2012.

Side Effects

The side effects of Saridegib were found to be severe in clinical trials. These included muscle cramps, hair loss, weight loss, taste disturbance, and fatigue. Due to these adverse effects, the development of Saridegib was discontinued.

Future Research

Despite the discontinuation of Saridegib, research into the Hedgehog signaling pathway and its role in cancer continues. Other inhibitors of the pathway are currently being developed and tested, with the hope of finding a drug that can effectively target this pathway with fewer side effects.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!